NorthWest Biotherapeutics Inc (NWBO)

[Lykiri]

EANO Past-President 2020-2022
Matthias Preusser, Vienna, Austria

flipper44,
EANO ANNUAL REPORT 2021
Professor Susan Short, a Professor of neuro-oncology at Leeds University, has been elected by the Executive EANO Board to become the next EANO President (2022-2024)

New President-elect: Professor Susan Short
“I am delighted and honoured to have the opportunity to serve EANO as President. I look forward to working with the whole community to build forward-looking, diverse and impactful research and education activity in Neuro-oncology” Prof. Susan Short

Professor Susan Short, a Professor of neuro-oncology at Leeds University, has been elected by the Executive EANO Board to become the next EANO President (2022-2024) and will therefore hold the position of President-Elect for the next year. She has been involved with EANO since 2000, has worked for the EANO Executive board between 2006-2010, and is currently the co-chair of our Disparity Committee. As EANO president she will focus on consolidating EANO’s reputation as the pre-eminent neuro oncology group in Europe with a critical role in supporting and developing neuro oncology practice, education and research across the whole of the continent, on increasing membership and ensuring high level multi-disciplinary engagement as well as developing closer ties with other relevant organisations. We are looking forward to her presidency.

https://www.eano.eu/fileadmin/user_upload/0078_EANO_Annual_Report_2021.pdf

JAMA ONCOLOGY

Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma
A Phase 3 Prospective Externally Controlled Cohort Trial

Comment
November 30, 2022
The need to report as-planned analyses and the weakness of historical controls
Dr. Matt Williams, London
Dr. Paul Sanghera, Birmingham
Prof. Susan Short, Leeds
Dr. Anup Vinayan, London
Dr. Juliet Brock, Oxford
Dr. Chris Herbert, Bristol
Dr. Joanne Lewis, Newcastle
Dr. Shaveta Mehta, Liverpool
https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847